# Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus

> **NCT04519073** · PHASE1 · COMPLETED · sponsor: **Virometix** · enrollment: 60 (actual)

## Conditions studied

- Acute Bronchiolitis Due to Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** V-306 candidate vaccine

## Key facts

- **NCT ID:** NCT04519073
- **Lead sponsor:** Virometix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-07
- **Primary completion:** 2022-03-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519073, "Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04519073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*